Home > Formulary : Adult > Recent Decisions > 2013 >
Decisions 10th September 2013
Recent JFG Decisions
At the meeting on the 10th September 2013 the following decisions / changes to the formulary were agreed:
New Drug Requests
Approved
Lixisenatide
- Approved for inclusion, TLS Green, first line.
Renavit®
- Approved for inclusion in the JF for the dietary management of water soluble vitamin deficiency in patients with chronic kidney disease in place of Dialyvit®. TLS blue for patients on renal dialysis.
Not approved
Linaclotide
- Rejected as the clinical evidence did not support the inclusion into the formulary although the JFG acknowledged that this was a novel drug and there would be an emerging evidence base.
Deferred
Artiss®
- The JFG was unable to consider the application fully due to insufficient clinical evidence provided at this time.
Teriparatide
- The JFG was unable to consider the application fully due to insufficient clinical evidence provided.
Specialised Commissioning
- No new statements
Shared Care Protocols
Methotrexate in Dermatology
- new SCP
Hydroxychloroquine in Dermatology
- new SCP
Change in TLS
Prucalopride
- change in TLS status from amber to blue on the advice of a specialist service
Tapentadol MR for chronic pain
- change form TLS Red to TLS amber once SCP is finalised
Insulin Degludec
- request for change from TLS red to amber was not approved
Other Decisions
- Natamycin - is commissioned by the CCG, UHB to submit a NDR